Spring Bank to Present at the Jefferies Virtual Global Healthcare Conference
Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH) announced its participation in the Jefferies Virtual Global Healthcare Conference from June 2-4, 2020.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH) announced its participation in the Jefferies Virtual Global Healthcare Conference from June 2-4, 2020. Martin Driscoll, the President and CEO, will present on June 2, 2020, from 4:00 PM to 4:25 PM EDT. The presentation will be accessible on the company's website. Spring Bank focuses on developing novel therapeutics for viral infections, inflammatory diseases, and cancers, with its lead candidate SB 11285 aimed at treating selected cancers. For more details, visit www.springbankpharm.com.
Details
News Market Reaction – SBPH
The recorded move for SBPH in the trading session of this news was +0.86%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
HOPKINTON, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that it will be participating in the Jefferies Virtual Global Healthcare Conference, taking place June 2-4, 2020.
Martin Driscoll, Spring Bank’s President and CEO, will be providing a corporate presentation on June 2, 2020 from 4:00pm to 4:25pm EDT.
The corporate presentation will be accessible in the Investors & Media section of the company's website at https://ir.springbankpharm.com/. There are no planned webcasts for this event.
About Spring Bank Pharmaceuticals
Spring Bank Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using its proprietary small molecule nucleotide platform. The company designs its compounds to selectively target and modulate the activity of specific proteins implicated in various disease states. The company is developing its STING product portfolio with its lead clinical product candidate, SB 11285, an intravenously-administered immunotherapeutic agent for the treatment of selected cancers, its STING antagonist compounds for the treatment of a broad range of inflammatory diseases and its STING agonist ADC program for potential oncology applications. For more information, please visit www.springbankpharm.com.
Investors:
LifeSci Advisors, LLC
Ashley R. Robinson
(617) 535-7742
Ashley@lifesciadvisors.com
Media:
McNeil, Gray & Rice
Kristin Nugent
Senior Account Supervisor
(617) 367-0100
Source: Spring Bank Pharmaceuticals, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.